Redesigner drugs
- PMID: 15286643
- DOI: 10.1038/nbt0804-953
Redesigner drugs
Abstract
Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
